Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer
Puma Biotech plunges on drug side effects
Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in South Korea | Business Wire
Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib
PumaBiotech (@pumabiotech) / Twitter
Puma Biotechnology
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Puma Biotechnology, Inc. | LinkedIn
PUMA BIOTECHNOLOGY, INC. FORM 10-K - Biotech Due Diligence
Puma Biotechnology
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Jobs with Puma Biotechnology
Puma Biotech Strikes Deal to Develop and Market its Breast Cancer Drug in China - Los Angeles Business Journal
Former Puma Biotech executive gets U.S. prison term for insider trading | Reuters.com
Puma Biotech Plunges on Sharp Drop in Cancer-Drug Sales - TheStreet
Puma Biotechnology
Puma Biotechnology up 15% after quarterly earnings beats (NASDAQ:PBYI) | Seeking Alpha
Puma Biotech shares slide after glimpse of trial data on cancer drug | Financial Times
Puma Biotechnology Announces $10 Million Private Placement | Business Wire
Puma Biotech Gets $100M Loan to Boost Breast Cancer Drug - Los Angeles Business Journal
